Pacific Biosciences of California Inc (PACB)

5.33
0.23 4.14
NASDAQ : Health Care
Prev Close 5.56
Open 5.58
Day Low/High 5.29 / 5.74
52 Wk Low/High 3.58 / 14.00
Volume 1.61M
Avg Volume 1.92M
Exchange NASDAQ
Shares Outstanding 92.68M
Market Cap 515.28M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pacific Biosciences Announces Fourth Quarter 2016 Financial Results

Pacific Biosciences Announces Fourth Quarter 2016 Financial Results

Product and Service Revenue Increases by 92% Over Same Period in Previous Year

More Than 115 Presentations And Posters Feature PacBio SMRT Sequencing To Decipher Complex Plant And Animal Genomes At Annual PAG Conference

More Than 115 Presentations And Posters Feature PacBio SMRT Sequencing To Decipher Complex Plant And Animal Genomes At Annual PAG Conference

Over 60 new plant and animal genomes assembled with PacBio data will be presented

Short Interest In Pacific Biosciences Of California Moves 13.4% Lower

Short Interest In Pacific Biosciences Of California Moves 13.4% Lower

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 2,487,057 share decrease in total short interest for Pacific Biosciences of California Inc , to 16,118,732, a decrease of 13.37% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

UPDATE -- Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

UPDATE -- Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

Structural Variant Detection, De Novo Assembly and Targeted Sequencing Applications Improved

Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

Structural Variant Detection, De Novo Assembly and Targeted Sequencing Applications Improved

Health Sector Down As Report of Industry Price Collusion Surfaces

Health Sector Down As Report of Industry Price Collusion Surfaces

The healthcare sector was dragged down by reports of price collusion and worse-than-expected third-quarter profits.

Pacific Biosciences of California Enters Oversold Territory (PACB)

Pacific Biosciences of California Enters Oversold Territory (PACB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Pacific Biosciences Of California, Inc. Announces Third Quarter 2016 Financial Results

Pacific Biosciences Of California, Inc. Announces Third Quarter 2016 Financial Results

Revenue Increases by 80% Over Same Period in Previous Year

PacBio Files ITC Patent Infringement Complaint Against Oxford Nanopore

PacBio Files ITC Patent Infringement Complaint Against Oxford Nanopore

Action Seeks ITC Investigation and Exclusion Order Against Infringing Single-Molecule Sequencing Products

First Week of June 2017 Options Trading For Pacific Biosciences of California (PACB)

First Week of June 2017 Options Trading For Pacific Biosciences of California (PACB)

Investors in Pacific Biosciences of California Inc saw new options begin trading this week, for the June 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

G10K And B10K Initiatives Select PacBio SMRT Sequencing For Next Phase Of Genome Projects

G10K And B10K Initiatives Select PacBio SMRT Sequencing For Next Phase Of Genome Projects

Sequel Systems to Be Used for High-Quality Vertebrate Genome Assemblies

Illumina Shares Hammered by Sales Forecast Cut

Illumina Shares Hammered by Sales Forecast Cut

Cantor Fitzgerald says Illumina's outlook revision is not likely to affect industry peers.

Commit To Buy Pacific Biosciences of California At $7.50, Earn 19.9% Annualized Using Options

Commit To Buy Pacific Biosciences of California At $7.50, Earn 19.9% Annualized Using Options

Investors eyeing a purchase of Pacific Biosciences of California Inc stock, but cautious about paying the going market price of $9.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $7.50 strike, which has a bid at the time of this writing of 70 cents.

Dovetail Genomics Adds PacBio SMRT Sequencing And Assembly To Its Services Menu

Dovetail Genomics Adds PacBio SMRT Sequencing And Assembly To Its Services Menu

- Dovetail customers can now incorporate PacBio's Single Molecule, Real-Time (SMRT) long-read sequencing into their genome assembly projects; companies to co-market Dovetail offering -

Today's Perilous Reversal Stock: Pacific Biosciences Of California (PACB)

Today's Perilous Reversal Stock: Pacific Biosciences Of California (PACB)

Trade-Ideas LLC identified Pacific Biosciences of California (PACB) as a "perilous reversal" (up big yesterday but down big today) candidate

Pacific Biosciences Releases New Software And Chemistry For Sequel System

Pacific Biosciences Releases New Software And Chemistry For Sequel System

Updates Demonstrate Company's Commitment to Continually Improving SMRT Sequencing Throughput, Read Length and Accuracy

Pacific Biosciences Of California, Inc. Announces Second Quarter 2016 Financial Results

Pacific Biosciences Of California, Inc. Announces Second Quarter 2016 Financial Results

Product and Service Revenue Increases by 51% Over Same Period in Previous Year

HistoGenetics Wins Multi-Year Contract For HLA Typing Using PacBio Sequencing

HistoGenetics Wins Multi-Year Contract For HLA Typing Using PacBio Sequencing

Company's Capabilities in PacBio's SMRT Sequencing a Key Factor in Winning Contract to Process Thousands of Samples Per Week

Relative Strength Alert For Pacific Biosciences of California

Relative Strength Alert For Pacific Biosciences of California

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Pacific Biosciences Of California (PACB) Weak On High Volume Today

Pacific Biosciences Of California (PACB) Weak On High Volume Today

Trade-Ideas LLC identified Pacific Biosciences of California (PACB) as a weak on high relative volume candidate

Cold Spring Harbor Laboratory Scientists Produce High-Quality Maize Transcriptome With PacBio SMRT Sequencing

Cold Spring Harbor Laboratory Scientists Produce High-Quality Maize Transcriptome With PacBio SMRT Sequencing

Findings of novel genes and corrections of previous mis-annotations published in Nature Communications